HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International

Stock News07-10

According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for HAIXI PHARMA (02637) on July 9th. The total value of securities deposited reached 2.013 billion Hong Kong dollars, representing 12.60% of its holdings.

A major shareholder of the company deposited 9.8733 million shares with CMB International Securities, resulting in an increase in the shareholder's holding proportion by 12.55%.

In a separate announcement, the company stated that its self-developed C019199 tablets have formally initiated a Phase III clinical trial (CTR20261818) for osteosarcoma patients who have failed at least two prior lines of treatment. The relevant information has been published on the drug clinical trial registration and information disclosure platform of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152440435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 09:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152440435","market":"nz","top_or_hot":-1,"title":"HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for <b>HAIXI PHARMA</b> (<b>02637</b>) on July 9th. The total value of securities deposited reached 2.013 billion Hong Kong dollars, representing 12.60% of its holdings.<br><br>A major shareholder of the company deposited 9.8733 million shares with CMB International Securities, resulting in an increase in the shareholder's holding proportion by 12.55%.<br><br>In a separate announcement, the company stated that its self-developed C019199 tablets have formally initiated a Phase III clinical trial (CTR20261818) for osteosarcoma patients who have failed at least two prior lines of treatment. The relevant information has been published on the drug clinical trial registration and information disclosure platform of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-10 09:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for <b>HAIXI PHARMA</b> (<b>02637</b>) on July 9th. The total value of securities deposited reached 2.013 billion Hong Kong dollars, representing 12.60% of its holdings.<br><br>A major shareholder of the company deposited 9.8733 million shares with CMB International Securities, resulting in an increase in the shareholder's holding proportion by 12.55%.<br><br>In a separate announcement, the company stated that its self-developed C019199 tablets have formally initiated a Phase III clinical trial (CTR20261818) for osteosarcoma patients who have failed at least two prior lines of treatment. The relevant information has been published on the drug clinical trial registration and information disclosure platform of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161027","symbol_name":"证券","start_time":0,"source_url":"","article_id":"1152440435","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152440435","pubTimestamp":1783645348,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for HAIXI PHARMA (02637) on July 9th. The total value of securities deposited reached 2.013...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","02637":"海西新药","BK1191":"制药"},"translate_title":"海西药业录得20.1亿港元存托证券，大股东将股份转让给招银国际","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"02637":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for HAIXI PHARMA (02637) on July 9th. The total value of securities deposited reached 2.013 billion Hong Kong dollars, representing 12.60% of its holdings.A major shareholder of the company deposited 9.8733 million shares with CMB International Securities, resulting in an increase in the shareholder's holding proportion by 12.55%.In a separate announcement, the company stated that its self-developed C019199 tablets have formally initiated a Phase III clinical trial (CTR20261818) for osteosarcoma patients who have failed at least two prior lines of treatment. The relevant information has been published on the drug clinical trial registration and information disclosure platform of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152440435","isCrawlerRequest":true}